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Because of instability in eastern Afghanistan, new refu-
gees crossed into the federally administered tribal areas of 
northwestern Pakistan in 2002. In 2003, we investigated 
an epidemic of Plasmodium falciparum malaria in 1 of the 
camps. Incidence was 100.4 cases/1,000 person-years; in 
other nearby camps it was only 2.1/1,000 person-years. 
Anopheline mosquitoes were found despite an earlier spray 
campaign. Documented clinical failures at the basic health 
unit prompted a drug resistance survey of locally manufac-
tured sulfadoxine-pyrimethamine used for routine treatment. 
The in vivo failure rate was 28.5%. PCR analysis of the P. 
falciparum dihydrofolate reductase and dihyropteroate syn-
thase genes showed no mutations associated with clinical 
failure. However, chemical analysis of the drug showed that 
it was substandard. As global incidence decreases and epi-
demics become more of a threat, enhanced quality assur-
ance of control interventions is essential.
Epidemics make a major contribution to the global im-pact of malaria (1). Predisposing factors include level 
of disease endemicity, immune status of the population, 
changes in vector–person contact, unusual weather phe-
nomena, confl ict or mass population movement, and the 
capacity of public health systems to detect epidemics and 
respond (1). Epidemic malaria is more common in areas of 
mesoendemicity or hypoendemicity (2,3).
Detection and control require rapid reporting of reliable 
surveillance data and the capacity to analyze and interpret 
trends. An epidemic can be defi ned as a “sharp increase in 
the frequency of malaria transmission that exceeds by far 
the inter-seasonal variation normally experienced” (4). Dis-
tinguishing a seasonal increase from an epidemic may re-
quire comparison with historic data from the same locality 
(1,5), but such data may be unavailable or unreliable. This 
fi nding is particularly true for regions where confl ict leads 
to population upheaval, creation of new settlements, and 
breakdown of health services (6,7). Adequate control re-
quires rapid response using health information campaigns, 
reinforced diagnostic services, effective short-course drugs, 
preventative measures, and political commitment.
The Federally Administered Tribal Areas (FATA) of 
northwestern Pakistan are semiautonomous, tribally gov-
erned agencies running north–south along the western 
border with Afghanistan. These are areas of rugged terrain 
along a porous and unstable border (the Durrand Line). The 
region has been an area of complex emergency since 1979 
and is currently unstable because of confl ict between Paki-
stan’s armed forces and insurgents in FATA and the ongo-
ing confl ict across the Durrand Line in Afghanistan.
We describe an epidemic of Plasmodium falciparum 
malaria among Afghan refugees who in 2002 had fl ed to 
FATA after drought and war in the neighboring Afghan 
provinces of Nangahar, Paktia, and Khost. We report the 
causes and epidemiology of the outbreak and the health 
service response.
Materials and Methods
Study Area and Health Services
For 3 decades, FATA has hosted one of the largest 
refugee migrations, beginning with >3 million Afghans 
crossing the border to escape the confl ict in Afghanistan 
(8). In response to the initial refugee crisis, >200 refugee 
camps were established under the mandate of the United 
Nations High Commissioner for Refugees (UNHCR) and 
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the Pakistan Commissionerate for Afghan Refugees. Pri-
mary healthcare was provided by nongovernmental organi-
zations through basic health units (BHUs) in each camp.
Ashgaroo camp was formed in 2002 in Khurram Agen-
cy, near the town of Parachinar, after drought and confl ict in 
the neighboring Afghan provinces of Nangahar, Paktia, and 
Khost forced several thousand refugees to cross the border. 
Refugees were provided with tarpaulins and used locally 
acquired mud and straw to construct rudimentary shelters. 
The camp was situated in an area of semiarid grassland. 
A few kilometers to the east, the land is irrigated by the 
Khurram River, a tributary of the Indus River. Rice, wheat, 
and maize are grown in this region by the local Pakistani 
population. The UNHCR demographic surveillance system 
showed that the population of the camp varied between 
8,000 and 10,000 (HealthNet TPO, 2005, unpub. data).
Malaria is seasonal in the region; ≈85% of cases are 
caused by P. vivax and the remainder by P. falciparum (6). 
An integrated malaria control program was run through the 
UNHCR network of clinics and fi eld laboratories; technical 
support was provided by the nongovernmental organization 
HealthNet TPO. First-line treatments were sulfadoxine-py-
rimethamine (SP) for patients with P. falciparum malaria 
and chloroquine for patients with P. vivax malaria.
Analysis of Malaria Surveillance Data
Routine malaria surveillance data were the primary 
data source for analysis of the epidemic. These data were 
compiled each month by BHU staff in each refugee camp 
and transmitted through the health information system to 
provincial health authorities. Health services were free and 
most refugees used the BHUs. Outpatients with suspected 
malaria were referred to a microscopist for diagnosis. Pa-
tients with confi rmed malaria were treated according to lo-
cal guidelines with chloroquine for P. vivax and SP for P. 
falciparum or mixed infections. The quality assurance sys-
tem, using blinded cross-checking of positive and negative 
slides, ensured a fi eld microscopy accuracy >98% (9).
Case records entered in malaria registers consisted of 
age, sex, slide result, and treatment given. The total number 
of slides examined and the age and sex of persons with P. 
vivax, P. falciparum, and mixed infections were submit-
ted each month to HealthNet TPO and collated by camp 
into monthly summaries of numbers of malaria cases, slide 
positivity rate, and incidence.
To compare with Ashgaroo data, 2 other datasets were 
accessed from the surveillance data of the Kurram Agency 
for 2002–2004. The fi rst dataset was summary data for the 
camps of Bassoo and Old Bagzai which were established 
for new refugees at the same time as Ashgaroo. The sec-
ond dataset was summary data for 6 camps established in 
Kurram in the early 1980s; these camps have longer es-
tablished health services. All camps were similar in that 
they were occupied by Afghan refugees and situated in the 
same locality (Khurram Agency). The older camps had 
mud houses and a well-established health system. Newer 
camps were a mixture of tarpaulin shelters with mud walls, 
were more remotely situated, lacked electricity, and had a 
recently established health center.
Analysis of the epidemic compared 3 parameters: 
number of cases of malaria in persons who came to BHUs, 
slide positivity rate (no. cases positive for malaria/total no. 
slides examined), and incidence rate (no. cases/total per-
son-months at risk). These parameters were estimated by 
using population data from UNHCR and passive surveil-
lance data from camp BHUs.
Monitoring of Drug Resistance
Monitoring of drug resistance was conducted in re-
sponse to reports of treatment failure. Patients with micro-
scopically confi rmed P. falciparum infection gave informed 
consent and were enrolled in an in vivo drug resistance 
study. These patients were administered the same locally 
manufactured SP used by BHU health workers for routine 
treatment. The dose administered was based on weight of 
the patient and was noted on patient record forms. Patients 
were monitored for vomiting. Patients returned for consul-
tation and collection of blood smears at weekly intervals 
for 42 days or at any time if symptoms recurred. Any ab-
sentee was followed up in their shelters and classifi ed as 
lost to follow-up if absent for >2 consecutive days. Treat-
ment failures in patients were defi ned by using criteria of 
the World Health Organization (WHO) (10); these patients 
were treated with mefl oquine. A blood sample was ob-
tained at the time of enrollment for detection of mutations 
in the P. falciparum dihydrofolate reductase (Pfdhfr) and 
dihyropteroate synthase (Pfdhps) genes, which are known 
to be associated with antifolate resistance (11,12).
An in vivo resistance study was conducted concurrent-
ly by HealthNet TPO in 3 long-established refugee camps 
50–100 km north of the study site and situated outside the 
tribal areas. As in Ashgaroo, patients were enrolled if they 
had microscopically confi rmed P. falciparum malaria but 
these patients were treated with SP (500 mg sulfadoxine 
and 25 mg pyrimethamine) (Fansidar; Roche, Basel, Swit-
zerland) provided by WHO. Supervision was the same as 
in Ashgaroo, with a 42-day observation period. Slides from 
both trials were read by 2 microscopists and discordant 
slides were read by a third. In both studies, the primary out-
come was defi ned as any malaria treatment failure, whether 
clinical or parasitologic, over the 42-day observation peri-
od. Simple proportions and univariate and multivariate lo-
gistic regression analyses were used to assess associations 
with failure, correcting for sex and age (STATA version 8; 
StataCorp., College Station, TX, USA).
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Drug Quality Evaluation
SP (Fansidar; Roche) and the locally manufactured SP 
were analyzed for quantity of active ingredient by using 
in vitro dissolution testing protocols according to proce-
dures outlined in the United States Pharmacopeia and by 
high-performance liquid chromatography (HPLC). The test 
for content expresses the amount of active ingredient as a 
percentage of the label claim, and the test for dissolution 
determines the amount of active ingredient released and 
available for absorption (13).
Tablet dissolution was performed in the Pharma Test 
PT 017 dissolution apparatus (Pharma Test Apparatebau, 
Hainburg, Germany) and analyzed by using HPLC (14). 
Drug quality was assessed by comparing the amount of ac-
tive ingredient in eluents of each dissolution sample against 
a known concentration of the standard for sulfadoxine and 
pyrimethamine after HPLC analysis.
Vector Control
Entomologic investigation was conducted by space 
spray collection of mosquitoes conducted in 5 randomly se-
lected compounds (animal sheds and sleeping areas) in Ash-
garoo camp on 1 day. Windows were sealed and rooms were 
sprayed with a pyrethroid spray canister. Specimens were 
collected from white fl oor sheets and identifi ed to species.
Results
Initial Outbreak Investigation and Response
In late June 2003, cases of P. falciparum malaria were 
reported in Ashgaroo camp. Because cases are not usually 
seen before mid-August, an investigation was mounted that 
strengthened case reporting and treatment guidelines. By Au-
gust, the number of cases in Ashgaroo had increased above 
the usual level for the time of year. The epidemic response 
team directed to the camp confi rmed a high vector density. A 
total of 717 anopheline specimens were collected from the 5 
compounds, mostly from animal sheds. Of these specimens, 
690 (96%) were Anopheles subpictus, 6 were A. stephensi, 
14 were A. culicifacies, and data for 7 were not available. 
Anopheline larvae were found in several locations, mainly 
in borrow pits recently dug by the refugees for construction 
of mud shelters. Typically, borrow pits were several meters 
wide and deep and fed by water drained from the camps’ 
water tanks or from unseasonable rain, which maintained 
adequate water levels for mosquito breeding.
The epidemic response was to ensure adequate sup-
plies of drugs, provide diagnostic and treatment services 
24 hours per day, and apply larvicide to confi rmed breed-
ing sites. Insecticide-treated nets were made available at a 
highly subsidized price (UNHCR policy at the time). Ac-
tive case detection was not carried out until October and 
November.
Epidemic Trends
Malaria Cases
The trend in number of malaria cases recorded dur-
ing 2002–2004 is shown in Figure 1. A steep increase in 
the number of P. vivax cases in the 3 new camps of Ash-
garoo, Bassoo and Old Bagzai began in June 2002 at the 
beginning of the transmission season and peaked in August 
2002 (Figure 1). In 2003, the increase in cases started much 
earlier, a normal occurrence because of delayed patency or 
relapse of cases from the previous year’s transmission. In-
secticide spraying of Bassoo and Old Baghzai in 2003 ap-
peared to reduce the number of P. vivax and P. falciparum 
cases that otherwise occurred that summer by curtailing 
transmission.
The P. falciparum malaria epidemic in Ashgaroo de-
veloped rapidly from 17 cases in August 2003 to 438 in 
September 2003. By November, the number of cases (82) 
had decreased to levels expected for that time of year. Us-
ing routinely reported mortality data as the indicator, we 
did not observe excess deaths in the camp. Few co-infec-
tions were recorded (1 in 2002 and 22 in 2003).
Malaria Incidence
An unusually high incidence of P. vivax malaria was 
recorded in the 3 newly established refugee camps (Ash-
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Figure 1. Number of cases of A) Plasmodium falciparum and B) 
P. vivax malaria in refugee camps in Khurram Agency, Pakistan, 
2002–2004. Black lines indicate Ashgaroo camp, red lines indicate 
Bassoo and Old Bagzai camps combined, and blue lines indicate 
the remaining 6 older camps. 
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garoo, Old Bagzai, and Bassoo) in the summer of 2002 
(Table 1, Figure 2). Incidence of P. vivax (269 cases/1,000 
person-years) and P. falciparum malaria (32 cases/1,000 
person-years) was 15.6× higher (95% confi dence interval 
[CI] 14.7–16.7×] for P. vivax and 6.9× higher (95% CI 5.9–
8.1×) for P. falciparum than in the 6 remaining camps. The 
range in annual incidence of P. vivax malaria in the 3 new 
camps was similar (130–296 cases/1,000 person-years). In 
contrast, the annual incidence of P. falciparum malaria was 
similar in Ashgaroo (32 cases/1,000 person-years) and Bas-
soo (22 cases/1,000 person-years) but was ≈10× lower than 
the annual incidence of P. vivax malaria (269 cases/1,000 
person-years).
Tents and houses were sprayed with insecticide before 
the onset of the 2003 malaria transmission season. During 
2003, a total of 963 P. falciparum malaria cases were re-
corded in Ashgaroo (incidence 100.4/1,000 person-years). 
The incidence rate ratio relative to the previous year was 
3.1 (95% CI 2.8–3.5). Compared with rate ratios for camps 
at Bassoo and Old Bagzai, the incidence rate ratio in Ash-
garoo was 48.8 (95% CI 30.3–84.1). Compared with rate 
ratios for the 6 long-established camps, the ratio was 72.1 
(95% CI 58.5–89.7). The incidence of P. falciparum ma-
laria in Ashgaroo was only marginally lower than that for 
P. vivax malaria (P. falciparum 100.4/1,000 person-years 
vs P. vivax 142.6/1,000 person-years), whereas the P. vivax 
malaria:P. falciparum malaria incidence rate ratio for the 
region is usually of the order of 5:1.
Slide Positivity Rate
The slide positivity rate provides an opportunity to mea-
sure the proportion of febrile illness attributable to malaria. 
The advantage of this rate over estimates of incidence rate 
is that trends are unaffected by inaccuracies or changes in 
population. During epidemics, malaria positivity rates show 
a sudden increase. P. vivax positivity rates for the new camps 
in 2002 and 2003 were only 2.9× higher than for long-estab-
lished camps (Figure 3), and P. falciparum positivity rates 
for the new camps of Ashgaroo (4.7%) and Bassoo (3.6%) in 
2002 were also similar to those for the older camps (2.9%). 
However, in 2003, the P. falciparum positivity rate showed 
a marked increase for Ashgaroo (18.8%) and reached 50% 
positivity during the peak of the epidemic in October, a rate 
9× higher than for the neighboring camps.
Evaluation of Drug Effi cacy
In September 2003, staff reported that many patients 
were returning with recurrent malaria after treatment with 
SP. These cases were confi rmed microscopically and treat-
ed with mefl oquine, the second-line treatment. Using the 
in vivo drug resistance protocol, we recruited 169 patients 
with malaria cases at the clinic and who were treated with 
SP (Table 2). Selection was based on clinical symptoms, 
malaria parasitemia, and granting of informed consent. 
Eighteen (10.6%) patients were lost to follow-up. Of those 
completing the study, treatment was not successful in 43 
(28.5%) of 151 patients (Table 3). The comparison group 
showed a failure rate for treatment with SP from WHO of 
only 10% (4/40) (χ2 = 5.8, p = 0.02) (Table 3).
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Table 1. Annual incidence of Plasmodium vivax and P. falciparum malaria per 1,000 population in camps in Khuram Agency, Pakistan, 
2002–2003
2002 2003
Camp P. vivax P. falciparum P. vivax P. falciparum
Ashgaroo 268.9 32.3 152.3 100.4
Bassoo 296.1 22.0 283.6 1.1
Old Bagzai 130.6 3.5 275.3 4.2
Bassoo and Old Bagzai 226.5 14.2 280.9 2.1
Remaining 6 camps 15.9 3.4 12.5 1.4
Figure 2. Incidence per 1,000 person-months of A) Plasmodium 
falciparum and B) P. vivax malaria in refugee camps in Khurram 
Agency, Pakistan, 2002–2004. Black lines indicate Ashgaroo camp, 
red lines indicate Bassoo and Old Bagzai camps combined, and 
blue lines indicate the remaining 6 older camps. 
Malaria and Substandard Drugs, Pakistan, 2003
PCR was conducted on specimens from 81 persons; 
37 samples were taken on the day of enrollment and day 
of treatment failure and 35 had no matching enrollment 
sample. All patients in whom treatment was not success-
ful were analyzed for merozoite surface protein 2; all had 
recrudescent infections and not reinfections (5 samples did 
not yield a product). Analysis also assessed 5 loci on the 
Pfdhfr gene at positions 16, 50/51, 59, 108, and 164, and 
4 loci on the Pfdhps gene at positions 436/437, 540, 581, 
and 613. Among samples matched with treatment failures, 
only 1 specimen showed any mutation (A16V) in the Pfd-
hfr gene. Single mutations were found in 6 of the baseline 
samples, but none of these polymorphisms on their own 
have been associated with clinical failure (11,12).
Samples of SP tablets used for routine treatment and 
for the drug resistance study were found to be substandard. 
WHO has defi ned substandard drugs as “the genuine drug 
products which do not meet quality specifi cations set for 
them. If a drug, upon laboratory testing in accordance with 
the specifi cations it claims to comply with fails to meet the 
specifi cations, then it is classifi ed as a substandard drug.” 
By 30 minutes of dissolution, only 52% sulfadoxine (0.156 
mg/mL, n = 9) and ≈16% pyrimethamine (0.0025 mg/mL, 
n = 9) was detected against the stipulation that 60% (sul-
fadoxine 0.3 mg/mL and pyrimethamine 0.015 mg/mL) 
should be dissolved at this point. The dissolution profi le for 
Fansidar met stated tolerance limits, but the locally manu-
factured generic tablets did not. Content analysis by HPLC 
showed that the generic tablets contained greater amounts 
of correct active ingredients (126% sulfadoxine/tablet and 
128% pyrimethamine/tablet) than stated on the packaging. 
Because they failed to meet the criteria for dissolution tol-
erance, the drugs would not be released at the required dose 
(13).
Discussion
The malaria epidemic in Pakistan was intense, short-
lived, and controlled by a series of active and passive in-
terventions. Strengthening of health services, active case 
detection and treatment, larviciding of anopheline breed-
ing sites, and distribution of insecticide-treated nets each 
played their part, although separating their individual con-
tributions is not possible. The onset of cooler weather in 
November brought an end to transmission. That no excess 
deaths were recorded is surprising, especially with substan-
dard fi rst-line treatment. The well-trained health staff, a 
well-run and close-at-hand clinic offering free treatment, 
an effective second-line drug, and public awareness likely 
contributed to this absence of excess deaths.
A combination of factors propagated the epidemic. 
Digging of borrow pits provided a new habitat for vector 
breeding. Epidemiologic evidence suggests failure of the 
spray campaign. Although the Bassoo and Old Bagzai spray 
campaigns appear to have curtailed transmission, the fail-
ure in Ashgaroo may have been caused by several factors. 
Insecticide resistance would enable vector survival, but this 
seems unlikely because malaria was well controlled in the 
other sprayed camps and resistance to pyrethroids has not 
been observed in this region. Effective implementation of 
spray campaigns requires quality-assured insecticide, thor-
ough training and supervision of spray teams, and checks 
on operations. The third factor may have been defi cient in 
Ashgaroo.
In the year before the epidemic, chloroquine was used 
as fi rst-line treatment despite high resistance levels (15). 
This use would enable persistence of gametocytemia in 
some persons and a reservoir of infection (16). Evidence 
shows that gametocytes can persist for 1 year after infec-
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Figure 3. Slide positivity rate (% slides positive) for A) Plasmodium 
falciparum and B) P. vivax malaria in refugee camps in Khurram 
Agency, Pakistan, 2002–2004. Black lines indicate Ashgaroo camp, 
red lines indicate Bassoo and Old Bagzai camps combined, and 
blue lines indicate the remaining 6 older camps. 
Table 2. Enrollment characteristics of population from in vivo 
drug resistance survey conducted in Ashgaroo and concurrent 
drug study in Yakaghund camp, Pakistan, October 2003 
Characteristic Ashgaroo Yakaghund 
No. (%) patients 169 (79.0) 45 (21.0) 
% Male sex 41.8 66.7
Mean age, y (SD) 13.3 (11.9) 19.4 (13.2) 
No. (%) lost to folllow-up 18 (10.7) 5 (11.1) 
RESEARCH
tion (17). Submicroscopic gametocytemia detected by PCR 
indicates that the gametocyte reservoir is considerably 
higher than previously thought in areas of low or seasonal 
transmission (18,19).
In the Pakistan–Afghanistan region, only 1 epidemic has 
been reported recently, an outbreak of high-altitude malaria 
in Bamian, Afghanistan (20). There are similarities between 
that epidemic and the current one; cases were reported in 
June–August, when unusual environmental conditions en-
abled vector breeding, and population movement of infected 
refugees provided a source of cases into an area previously 
unaffected by malaria. This outbreak was circumscribed by 
the immune status of the affected population (nonimmune 
migrants) and the relative isolation of the camp.
An. subpictus mosquitoes were previously identifi ed in 
the region and are competent vectors in Sri Lanka (21,22). 
Two studies in the Pakistan Punjab recorded peak abun-
dance of An. subpictus mosquitoes in late summer and fall; 
the species occurred sympatrically with An. stephensi mos-
quitoes (23,24). Historically, An. subpictus mosquitoes are 
not a major vector in the Pakistan Punjab (25). In eastern 
Afghanistan, Rowland et al. (9) identifi ed An. stephensi mos-
quitoes and to a lesser extent An. culicifacies mosquitoes as 
the main vectors; few An. subpictus mosquitoes were found 
by an 18-month surveillance study, and none were positive 
for circumsporozoite protein. An. subpictus mosquitoes are 
known to breed in muddy pools and borrow pits and later 
in the season than other potential vectors (24,25). Although 
the present study provides some evidence for An. subpictus 
being a more common vector than previously thought, it is 
likely that An. stephensi and An. culicifacies, the primary 
vector species (9), which were also recorded in low numbers 
during the surveys, played a part in transmission earlier in 
the summer during June and July. By September, the densi-
ties of these 2 vectors may have waned, as recorded in other 
longitudinal studies in eastern Afghanistan and Pakistan 
Punjab, but during the main transmission period were likely 
to have been more abundant (9,23).
Few mixed infections were seen. A recent metaanaly-
sis (26) showed a negative association between P. falci-
parum and P. vivax but noted considerable heterogeneity 
related to prevalence of infection. Our data, which showed 
fewer P. vivax cases than expected in the epidemic period, 
indicated a suppressive effect of P. falciparum on P. vivax, 
as recently observed during a vector control campaign that 
controlled P. falciparum transmission but led to an increase 
in relapsed P. vivax cases (6).
The assessment of in vivo drug resistance was con-
ducted in anticipation that a problem with SP resistance 
rather than substandard local drugs would be uncovered. 
Further assessments involving molecular characterization 
of SP resistance genes, drug quality testing, and in vivo 
surveys using standardized SP established that substandard 
drugs were the cause of what initially appeared as resis-
tance. The drugs used routinely in the camp were procured 
centrally and distributed through local government organi-
zations. A substandard drug in wide circulation will inevi-
tably contribute to disease transmission and was undoubt-
edly a factor contributing to this epidemic. The substandard 
drugs were procured as a response to shortages. In surveys 
of other camps, standard SP showed a 90% cure, which 
indicated that low-level resistance may be an emerging 
problem in the study region. A distinction should be made 
between the more easily remedied use of poorly manufac-
tured substandard drugs reported and the alarming growth 
of counterfeit drugs in Southeast Asia (27).
As the global prevalence of malaria decreases because 
of initiatives to control or eliminate the disease, more areas 
will become mesoendemic or hypoendemic for malaria and 
detection and control of epidemics will acquire greater at-
tention. Elimination will not be easy in areas of complex 
emergency and population movement, and the uncontrolled 
production or use of substandard drugs will only add to the 
problem. Mechanisms to ensure quality of interventions are 
essential.
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Table 3. Frequency of treatment failure for infection with Plasmodium falciparum or P. vivax , by group, sex, and age, Pakistan, 
October 2003*  
Characteristic Failure rate (%) Crude OR (95% CI) Adjusted OR (95% CI) 
Group 
 Comparison group 4/40 (10.0) 1 1
 Ashgaroo 43/151 (28.5) 3.6 (1.2–10.7) 3.2 (1.0–10.1) 
Sex 
 M 27/90 (30.0) 1 1
 F 20/99 (20.2)† 0.6 (0.3–1.2) 0.5 (0.3–1.2) 
Age group, y 
 0–5 16/40 (40.0) 1 1
 6–10 21/72 (29.2) 0.6 (0.3–1.4) 0.6 (0.3–1.1) 
 11–20 4/33 (12.2) 0.2 (0.1–0.7) 0.3 (0.1–1.0) 
 >20 6/46 (13.0) 0.2 (0.1–0.6) 0.3 (0.1–0.8) 
*OR, odds ratio; CI, confidence interval. 
†Results exclude losses to follow-up. 
Malaria and Substandard Drugs, Pakistan, 2003
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